The OlympiA clinical study is investigating whether taking olaparib tablets twice a day for 12 months can reduce the risk of breast cancer coming back after all standard anticancer treatments have been completed. It is hoped that the study will show that olaparib improves the curability of patients with HER2 negative breast cancer and inherited BRCA1 or BRCA2 mutations, which may result in a new standard treatment for these breast cancer patients.

свернуть